OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a ...

Opko Health Inc. (NASDAQ:OPK) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on May 2, Edward Tenthoff from Piper Sandler reiterated a Buy rating on ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

Strategic Agreements: OPKO Health has been active on multiple strategic fronts.In March, the company partnered with Entera Bio to develop a once-daily oral GLP-1/glucagon dual agonist tablet targeting ...

Weston, Massachusetts Wednesday, June 11, 2025, 12:00 Hrs [IST] ...

OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. On average, equities analysts forecast that OPKO Health will post -0.25 EPS for the current year. Insiders ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

OPKO Health bought ModeX in 2022 for its immunotherapy tech, with a focus on oncology and infectious diseases. At present, we cannot recommend OPKO stock to retail value investors.

Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today.

OPKO Health ran into SEC-related issues in 2018 and its stock price has plummeted since. OPKO has a long history of operating losses, but it has the potential to change the situation.